Comprehensive molecular phenotyping of ARID1A -deficient gastric cancer reveals pervasive epigenomic reprogramming and therapeutic opportunities.
Chang XuKie Kyon HuangJia Hao LawJoy Shijia ChuaTaotao ShengNatasha M FloresMelissa Pool PizziAtsushi OkabeAngie Lay Keng TanFeng ZhuVikrant KumarXiaoyin LuAna Morales BenitezBenedict Shi Xiang LianHaoran MaShamaine Wei Ting HoKalpana RamnarayananChukwuemeka George Anene-NzeluMilad Razavi-MohseniSiti Aishah Binte Abdul GhaniSu Ting TayXuewen OngMing Hui LeeYu Amanda GuoHassan AshktorabDuane SmootShang LiAnders Jacobsen SkanderupMichael A BeerRoger Sik Yin FooJoel Shi Hao WongKaushal SanghviWei Peng YongRaghav SundarAtsushi KanedaShyam PrabhakarPawel Karol MazurJaffer A AjaniKhay-Guan YeohJimmy Bok-Yan SoPatrick Boon-Ooi Tannull nullPublished in: Gut (2023)
-mutated GCs targeting both tumour-intrinsic (BRD4-assocatiated promoter activation) and extrinsic (NFKB immunomodulation) cancer phenotypes.